merck - Search News

Merck 2025 Sales Forecast Underwhelms

Bloomberg on MSN · 19h

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.

Business Insider · 1d

Merck Stock Loses 9% on Vaccine Shipment Halt to China

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical

The Associated Press - Busines… · 1d

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck stock slides

Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.

Seeking Alpha · 1d

Merck stock slides as 2025 earnings outlook misses estimates

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.

The Wall Street Journal on MSN · 1d

Merck Earnings Rise; 2025 Outlook Hits Shares

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, although the drug company’s outlook for 2025 and a slide in sales of its HPV vaccine hit shares.

9h

Merck: Don't Fight The Tape, How Low Can It Go?

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

1don MSN

Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

19hon MSN

Merck Is Suffering From a Classic Pharma Problem

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

13h

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

11hon MSN

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

StockStory.org on MSN1d

Why Merck (MRK) Stock Is Falling Today

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results